ESTAs Loss Narrows 92% But Nine-Year Slide Continues

Establishment Labs (ESTA) reported fiscal 2025 Q4 earnings on Feb 27, 2026, marking a 45.2% year-over-year revenue increase to $64.62 million. The company narrowed its net loss by 92.4% to $-2.62 million, with EPS improving from -$1.20 to -$0.09. Despite these gains, sustained losses over nine years highlight ongoing challenges.

Revenue

Total revenue surged 45.2% year-over-year to $64.62 million, outpacing the $44.51 million reported in 2024 Q4. This growth underscores strong market demand for the company’s products.

Earnings/Net Income

Establishment Labs significantly reduced its net loss to $-2.62 million in 2025 Q4, a 92.4% improvement from the $-34.53 million loss in 2024 Q4. Earnings per share (EPS) narrowed to -$0.09 from -$1.20, reflecting a 92.6% reduction in losses. However, the company continues to post losses, which have persisted for nine consecutive years in this quarter. While this progress is notable, the persistent financial headwinds indicate the need for sustained operational improvements to achieve profitability.

Price Action

The stock price of Establishment Labs has surged 21.17% month-to-date and gained 3.55% during the most recent full trading week.

Post-Earnings Price Action Review

The strategy of buying ESTA shares following a revenue drop quarter-over-quarter on the report release date and holding for 30 days resulted in a -9.50% return, far underperforming the benchmark’s 57.22% gain. This led to an excess return of -66.72% and a CAGR of -2.48%, underscoring the strategy’s poor risk-adjusted performance. The high maximum drawdown of 77.62% and a Sharpe ratio of -0.03 further emphasize the significant risks associated with this approach.

CEO Commentary

John Chacón-Quirós, CEO, emphasized the company’s progress in reducing losses while highlighting robust U.S. demand for its innovative products. “Despite ongoing challenges, we are confident in our strategic initiatives to drive growth through the Motiva, Preservé, and Mia platforms,” he stated. The CEO acknowledged the need for continued focus on operational efficiency and market penetration to achieve long-term profitability.

Additional News

In February 2026, Establishment Labs announced a revised leadership structure, appointing Cassandra “Sandra” Harris as CFO, replacing Raj Denhoy, who transitioned to a global strategy role. This reshuffle aims to align financial oversight with the company’s U.S. expansion goals. Additionally, the firm issued 2026–2027 revenue guidance projecting over 25% annual growth and positive cash flow, signaling optimism about its market position. The company also reported a 20% U.S. market share in augmentation products by year-end, underscoring its competitive positioning in key segments.